by No difference for B lymphocytes was detected between the vector treated groups (Physique3B). infiltrates or autoantibody levels was detected, statistically significant increased levels of tumor growth factor-1 and decreased levels of interleukin-5, interleukin-12p70 and interleukin -17 were detected in the salivary glands. In contrast, plasma levels showed significantly decreased levels of tumor growth factor-1 and increased levels of interleukin-4, interferon-, interleukin-10 and interleukin-12p70. == Conclusions == Our findings suggest that expression of tumor necrosis factor inhibitors in the salivary gland can have a negative effect on salivary gland function and that other cytokines should be explored as points for therapeutic intervention in Sjgren’s syndrome. == Introduction == Sjgren’s syndrome (SS) is usually a systemic autoimmune disorder affecting secretory tissue, including the lacrimal and salivary glands (SGs), resulting in keratoconjunctivitis sicca and xerostomia. SS is usually characterized by mononuclear cell infiltrates in the salivary and lacrimal glands as well as the presence of autoantibodies in serum. Other organ systems may be involved as well and around 5% of the patients develop B cell lymphoma [1,2]. There is still an unmet need for an effective treatment of SS. Anti-tumor necrosis factor (TNF) therapies have been widely and successfully used several chronic autoimmune diseases, such as rheumatoid arthritis (RA) and Crohn’s disease. Clinical trials with anti-TNF antibodies and etanercept showed improvement in 60 to 70% of the RA patients [3,4]. Patients with SS have been reported to have elevated Ozenoxacin serum pro-inflammatory cytokine levels compared with normal volunteers [5,6] and TNF is also overexpressed in the SGs of SS patients [7]. However, the use of anti-TNF brokers in patients with the autoimmune disease SS has shown conflicting results [8,9]. Beneficial results were shown in an open study, while inefficacy of anti-TNF was shown in Ozenoxacin a randomized, double-blind, placebo-controlled trial. TNF promotes inflammation by stimulating and inducing other inflammatory cytokines and adhesion molecules and is a key player in the cytokine balance [4]. In contrast, TNF can also exhibit anti-inflammatory Ozenoxacin activities, for instance by blocking the development of autoreactive T cells [10]. Moreover, adoptive transfer of ex lover vivo TNF treated splenocytes from autoimmune diabetic female non-obese diabetic (NOD) mice into irradiated pre-diabetic male mice prevented the development of hyperglycemia in 80% of the recipients. Recently, a T-cell based mechanism has been proposed to explain the dual effect of anti-TNF therapy in the treatment of autoimmune diseases in which TNF can function as a pro-inflammatory cytokine as well as an anti-inflammatory immunoregulatory molecule by altering the balance of regulatory T cells [11]. The National Institute of Dental care and Craniofacial Research (NIDCR) Sjgren’s medical center has previously investigated the efficacy of systemic etanercept Ozenoxacin treatment in SS patients and could not demonstrate clinical benefit [12]. Follow-up studies of cytokine levels in these patients before and after treatment revealed no decrease in TNF and other pro-inflammatory cytokines [13,14]. The reasons for the failed clinical trials are not well comprehended, but it is usually conceivable that the effects would be different if a more localized approach was used. Gene therapy offers the possibility to engineer cells to express therapeutic proteins locally at high levels. Previously, we reported successful gene transfer of interleukin (IL)-10 and vasoactive intestinal peptide (VIP) to mouse SGs Rabbit Polyclonal to SLC25A31 [15,16]. To investigate the effects of local TNF blockade using gene therapy, we evaluated the effect of a locally expressed TNF inhibitor around the SG function and histopathology in the NOD model of SS. == Materials and methods == == Cell lines == Human embryonic kidney 293T cells were produced in DMEM (Invitrogen, Ozenoxacin Carlsbad, CA, USA). This medium was supplemented with 10% heat-inactivated fetal bovine serum (FBS, Life Technologies, Rockville, MD, USA), 2 mM L-glutamine, penicilline (100 U/ml), and streptomycin (100 g/ml; Biofluids, Rockville, MD, USA) as previously explained [15]. Human fibrosarcoma (WEHI) cells were produced in RPMI 1640 (Invitrogen). This medium was supplemented with 10% FBS, 2.
